Patient Presents With Flank Pain

Poll

A 43-year-old woman presents with pain in the right flank. A kidney mass is found on imaging. What is your diagnosis?

A 43-year-old woman presents with pain in the right flank. A kidney mass is found on imaging, and a biopsy is performed.

What is your diagnosis?

A. Papillary renal cell carcinoma
B. Clear cell renal cell carcinoma
C. Wilms tumor
D. Mucinous tubular and spindle cell carcinoma
Recent Videos
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content
All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.

Personalized Vaccines Elicit Anti-Cancer Immune Responses in Kidney Cancer

Roman Fabbricatore
February 6th 2025
Article

All 9 patients in a phase 1 trial testing a neoantigen-targeting personalized cancer vaccine in renal cell carcinoma had no recurrence at data cutoff.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC

Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC

Tim Cortese
January 3rd 2025
Article

TLX250-CDx elicited a mean sensitivity of 85.5% and a mean specificity of 87.0% in patients with indeterminate renal masses in the phase 3 ZIRCON trial.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Highlighting Advocacy Impacts on Funding for Kidney Cancer Research

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 16th 2024
Podcast

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

FDA Approves New Formulation of Pazopanib Tablets in RCC, Sarcoma

Russ Conroy
December 5th 2024
Article

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

Addressing Gaps in Education for Non–Clear Cell RCC

Addressing Gaps in Education for Non–Clear Cell RCC

ONCOLOGY Staff
November 19th 2024
Article

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.